Roche, Repare sign $1.3B cancer therapy deal

Roche has inked a potential $1.3 billion deal with Repare Therapeutics to gain worldwide rights to an experimental cancer treatment option for patients with significant unmet medical needs across a range of tumor types.

The license and collaboration agreement is based on the development and commercialization of Quebec-based Repare's lead pipeline candidate, camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for the treatment of tumors with specific synthetic-lethal genomic alterations including those in the ATM gene (Ataxia-Telangiectasia mutated kinase). The precision oncology asset, designed to attack genetic defects in cancer tumors, is currently in phase 1/2 clinical development.

Under the terms of the agreement, Repare will receive a $125 million upfront payment, and is eligible to receive up to $1.2 billion in potential clinical, regulatory, commercial and sales milestones, including up to $55 million in potential near-term payments, and royalties on global net sales.

Roche will assume the development of camonsertib with the potential to expand development into additional tumors and multiple combination studies.